Technical Analysis for NMRA - Neumora Therapeutics, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 9.15 | 0.99% | 0.09 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | 0.99% | |
| New 52 Week Low | Weakness | 0.99% | |
| Wide Bands | Range Expansion | 0.99% | |
| Down 3 Days in a Row | Weakness | 0.99% | |
| Oversold Stochastic | Weakness | 0.99% | |
| New 52 Week Closing Low | Bearish | -4.59% | |
| Multiple of Ten Bearish | Other | -4.59% |
| Alert | Time |
|---|---|
| Up 2% | about 21 hours ago |
| Up 1% | about 21 hours ago |
| Fell Below Previous Day's Low | about 21 hours ago |
| Down 2 % | about 21 hours ago |
| Down 1% | about 21 hours ago |
Get a Trading Sidekick!
- Earnings date: 02/28/2024
Neumora Therapeutics, Inc. Description
Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Neumora’s therapeutic pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora’s work is supported by an integrated suite of translational, clinical, and computational tools to generate insights that can enable precision medicine approaches. Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients suffering from brain diseases. Neumora has operations in the Greater Boston Area and South San Francisco.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Neuroscience Drug Development Neurodegenerative Diseases Clinical Neuroscience
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 21.0 |
| 52 Week Low | 8.82 |
| Average Volume | 647,291 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 14.75 |
| 20-Day Moving Average | 12.12 |
| 10-Day Moving Average | 10.19 |
| Average True Range | 0.96 |
| RSI (14) | 24.24 |
| ADX | 32.89 |
| +DI | 9.39 |
| -DI | 36.18 |
| Chandelier Exit (Long, 3 ATRs) | 12.07 |
| Chandelier Exit (Short, 3 ATRs) | 11.70 |
| Upper Bollinger Bands | 16.16 |
| Lower Bollinger Band | 8.08 |
| Percent B (%b) | 0.13 |
| BandWidth | 66.64 |
| MACD Line | -1.48 |
| MACD Signal Line | -1.25 |
| MACD Histogram | -0.2354 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 9.89 | ||||
| Resistance 3 (R3) | 9.86 | 9.58 | 9.76 | ||
| Resistance 2 (R2) | 9.58 | 9.40 | 9.60 | 9.72 | |
| Resistance 1 (R1) | 9.37 | 9.28 | 9.48 | 9.40 | 9.68 |
| Pivot Point | 9.09 | 9.09 | 9.15 | 9.11 | 9.09 |
| Support 1 (S1) | 8.88 | 8.91 | 8.99 | 8.91 | 8.62 |
| Support 2 (S2) | 8.60 | 8.79 | 8.62 | 8.58 | |
| Support 3 (S3) | 8.39 | 8.60 | 8.54 | ||
| Support 4 (S4) | 8.42 |
